Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02896101 · ClinicalTrials.gov registry record · Phase 3
Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis
A Phase 3 study, sponsored by Glenmark Pharmaceuticals Ltd. India.
- Completed
- Registry status
- Phase 3
- Development phase
- 755
- Enrollment target
NCT02896101 is a Phase 3 study that has completed, run by Glenmark Pharmaceuticals Ltd. India. The registered enrollment target is 755 participants.
The verdict
NCT02896101, a Phase 3 study, has completed, sponsored by Glenmark Pharmaceuticals Ltd. India.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 755 participants
- Enrollment target
Study Summary
This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) to the Marketed Product ELIDEL® (pimecrolimus) Cream, 1% (Valeant Pharmaceuticals North America LLC) in the Treatment of Mild to Moderate Atopic Dermatitis (AD).
Interventions
- DRUG Pimecrolimus Cream, 1%
- DRUG Elidel® (pimecrolimus) Cream
- DRUG Placebo of Pimecrolimus Cream, 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 755 participants |
| Start Date | 2016-08 |
| Est. Completion | 2017-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02896101
The ClinicalTrials.gov registry entry for NCT02896101 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 755 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glenmark Pharmaceuticals Ltd. India, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pimecrolimus Cream, 1% is the first listed.
NCT02896101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02896101 about?
NCT02896101 is a clinical study titled "Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis". This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) to the Marketed Product ELIDEL® (pimecrolimus) Cream, 1% (Valeant Pharmaceuticals North America LLC) ...
What is the current status of trial NCT02896101?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 755 participants. The study started on 2016-08. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02896101?
The interventions under investigation include: Pimecrolimus Cream, 1% (DRUG), Elidel® (pimecrolimus) Cream (DRUG), Placebo of Pimecrolimus Cream, 1% (DRUG).
Who is sponsoring clinical trial NCT02896101?
This trial is sponsored by Glenmark Pharmaceuticals Ltd. India, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.